AURKB and cancer: These results suggest that MPS1 inhibitors may sensitise cell lines that were otherwise unresponsive to Aurora B inhibitors (Figure 8C–8D) and the combination of MPS1 and Aurora B inhibitors may have potential use as an anti-cancer therapy in the clinic.